ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-558-2871
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$124.90 million
Profitability
Miscellaneous
Employees425
OptionableOptionable
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.08. The biopharmaceutical company had revenue of $58.31 million for the quarter, compared to the consensus estimate of $56.31 million. ACADIA Pharmaceuticals had a negative return on equity of 88.18% and a negative net margin of 119.62%. The business's revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.53) EPS. View ACADIA Pharmaceuticals' Earnings History.
When is ACADIA Pharmaceuticals' next earnings date?
What price target have analysts set for ACAD?
10 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' shares. Their forecasts range from $17.00 to $60.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $31.70 in the next year. This suggests a possible upside of 50.5% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.
What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/17/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $30 price target on ACADIA. We recently hosted investors for a meeting with ACAD management on our Post ASH-Thrash Bus Tour. One focus of investor interest was the progress made by ACADIA on the NUPLAZID franchise since the removal of the safety concern overhang precipitated by what we view as an unfounded negative media article regarding the drug in PDP. Recall that in September 2018, the FDA announced that the label for NUPLAZID adequately characterized the known risks and that the agency still viewed benefits as outweighing risks for patients with PDP, especially in light of alternative off-label antipsych drugs." (12/5/2018)
- 3. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%)." (11/1/2018)
Has ACADIA Pharmaceuticals been receiving favorable news coverage?
News stories about ACAD stock have trended extremely positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG) and Alkermes (ALKS).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, CEO & Director (Age 58)
- Dr. Srdjan R. Stankovic, Pres (Age 62)
- Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
- Ms. Elena Ridloff C.F.A., CFA, Interim CFO & Sr. VP of Investor Relations
- Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)
Who are ACADIA Pharmaceuticals' major shareholders?
ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.54%), First Midwest Bank Trust Division (0.13%), Virtu Financial LLC (0.02%) and Meeder Asset Management Inc. (0.00%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Which institutional investors are selling ACADIA Pharmaceuticals stock?
ACAD stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Which institutional investors are buying ACADIA Pharmaceuticals stock?
ACAD stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Virtu Financial LLC and Meeder Asset Management Inc.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy shares of ACADIA Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $21.07.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $2.64 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.
What is ACADIA Pharmaceuticals' official website?
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
